Avanir says migraine treatment approval unlikely in November

November 7, 2014 1:54 PM

1 0

(Reuters) - Avanir Pharmaceuticals Inc said it was unlikely that its experimental migraine drug-device would win U.S. Food and Drug Administration approval by the scheduled timeline.

The FDA has raised questions regarding some data submitted as part of the marketing application, the company said on Friday. [ID:nPn10cYbX]

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page